Insight Genetics specializes in advanced molecular and multivariate assay development, focusing on precision medicine to enhance drug discovery and clinical trials. Their offerings include a proprietary immuno-oncology platform, custom tumor mutational burden (TMB) panels, and a variety of sequencing services such as next-generation sequencing (NGS) and whole-exome sequencing. They also provide targeted PCR panels, multiplex PCR assays, and real-time PCR in vitro diagnostic (IVD) development. Their capabilities extend to converting RNA expression signatures into targeted NGS or multivariate PCR assays, as well as developing proprietary assays for predicting immune therapy responses.

The company emphasizes a platform-agnostic approach to assay design, development, and validation, which supports the entire spectrum of drug development from early-stage testing to clinical trial assays and IVD offerings. Their laboratory is ISO- and CLIA-certified, CAP-accredited, and compliant with Good Clinical Practice (GCP), ensuring high-quality standards in processing clinical trial samples. Insight Genetics collaborates with leading diagnostic and pharmaceutical companies, providing support for FDA and regulatory submissions, and has successfully developed multiple validated diagnostic tests through their integrated laboratory, bioinformatics, and biostatistics teams.

United States

Insight Genetics provides advanced diagnostic solutions that enable personalized cancer care and improve patient outcomes. We have a portfolio of assays that detect specific cancer biomarkers and an innovative platform technology for assay development. Our products and services have application in translational research, clinical diagnostics and drug discovery.

Insight Genetics

Company Details